For research use only. Not for therapeutic Use.
Aminobenzenesulfonic auristatin E-d8, a premium pharmaceutical research compound designed for advanced oncology and cytotoxic studies. As a deuterated analog of Aminobenzenesulfonic auristatin E, it offers enhanced stability and improved pharmacokinetic properties. Aminobenzenesulfonic auristatin E-d8 is ideal for use in pharmacological and biochemical research, providing precise and reliable data for your studies. This high-purity compound ensures consistent results, aiding in the development of novel cancer therapies. Trusted by leading laboratories, Aminobenzenesulfonic auristatin E-d8 is your go-to solution for cutting-edge cancer research. Unlock new possibilities in cancer treatment with Aminobenzenesulfonic auristatin E-d8, where innovation meets reliability.
| Catalog Number | S000204 |
| Molecular Formula | C37H56D8N6O8S |
| Purity | ≥95% |
| IUPAC Name | (2R)-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[(4-aminophenyl)sulfonylamino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-2,3,4,4,4-pentadeuterio-2-[[(2S)-2-(dimethylamino)-3-methylbutanoyl]amino]-N-methyl-3-(trideuteriomethyl)butanamide |
| InChI | InChI=1S/C37H64N6O8S/c1-13-24(6)33(42(10)37(47)31(22(2)3)39-36(46)32(23(4)5)41(8)9)29(50-11)21-30(44)43-20-14-15-28(43)34(51-12)25(7)35(45)40-52(48,49)27-18-16-26(38)17-19-27/h16-19,22-25,28-29,31-34H,13-15,20-21,38H2,1-12H3,(H,39,46)(H,40,45)/t24-,25+,28-,29+,31+,32-,33-,34+/m0/s1/i2D3,3D3,22D,31D |
| InChIKey | AZVFJNPRFUTRNO-GSSOYSBSSA-N |
| SMILES | [2H][C@](C(=O)N(C)[C@@H]([C@@H](C)CC)[C@@H](CC(=O)N1CCC[C@H]1[C@@H]([C@@H](C)C(=O)NS(=O)(=O)C2=CC=C(C=C2)N)OC)OC)(C([2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])NC(=O)[C@H](C(C)C)N(C)C |
| Reference | [1]. Kevin HAMBLETT, et al. Anti-her2 biparatopic antibody-drug conjugates and methods of use. Patent WO2019173911A1. [2]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223. |
